NCT02029950View on ClinicalTrials.gov

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 16, 2013

Primary Completion Date

May 13, 2020

Study Completion Date

May 13, 2020

Conditions
Acute Myeloid LeukemiaChronic Myelomonocytic Leukemia-2High Risk Myelodysplastic SyndromeMyeloproliferative Neoplasm
Interventions
DRUG

Cytarabine

Given IV

DRUG

Daunorubicin Hydrochloride

Given IV

DRUG

Etoposide

Given IV

DRUG

Idarubicin Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Pomalidomide

Given PO

Trial Locations (3)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

06520

Yale University, New Haven

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02029950 - Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter